Methicillin-resistant Staphylococcus aureus (MRSA) is a major pathogen causing infections ranging from skin disorders to severe conditions like infective endocarditis. Its evolving resistance, including resistance to β-lactams and last-resort antibiotics, such as vancomycin, daptomycin, and linezolid, necessitates alternative therapies. This study investigates the synergistic efficacy of vancomycin and 3-hydrazinoquinoxaline-2-thiol (3HL) against 23 clinical MRSA isolates. Susceptibility testing was performed using broth microdilution and checkerboard assays, while in silico analyses assessed interactions between vancomycin and 3HL. Vancomycin exhibited minimum inhibitory concentrations (MICs) ranging from 0.25 to 1 µg/mL, whereas 3HL showed higher MICs of 16–32 µg/mL. Synergistic interactions were confirmed via checkerboard assays, with fractional inhibitory concentration index (FICI) values between 0.236 and 0.5, indicating enhanced vancomycin efficacy. Notably, vancomycin MICs decreased significantly when combined with 3HL. In silico docking revealed interactions with penicillin-binding protein 2a (PBP2a), suggesting promising therapeutic potential. Vancomycin exhibited superior docking scores (−8.9 kcal/mol) and stabilizing hydrogen bonds, effectively targeting key protein grooves. Both compounds demonstrated potential for overcoming PBP2a’s structural occlusions, suggesting their role in combating β-lactam-resistant strains through targeted protein inhibition and structural stabilization.
Background/Objectives: Smartphone-acquired throat images could support accessible pharyngitis assessment, but the performance and computational efficiency of lightweight models on such images require further evaluation. This study compared five lightweight models for predicting physician-consensus bacterial versus nonbacterial labels from smartphone throat images. Methods: We analyzed PGUPharyngitis, a public dataset of smartphone throat images collected in general practice. The final cohort comprised 635 patients, of whom 105 (16.5%) had bacterial physician-consensus labels. The reference outcome was physician consensus based on images and clinical information rather than microbiological testing. Five ImageNet-pretrained lightweight classifiers—four convolutional neural networks (CNNs; MobileNetV3-Small, EfficientNet-B0, ShuffleNetV2, and YOLO26n-cls) and one CNN–Transformer hybrid (MobileViT-XS)—were fine-tuned using patient-level five-fold cross-validation. Performance was assessed using area under the precision–recall curve (PR-AUC) and area under the receiver operating characteristic curve (AUROC), alongside computational efficiency. Device-only and clinical-variable logistic-regression models provided non-image comparisons. Results: Mean PR-AUC across folds ranged from 0.317 to 0.372 and AUROC from 0.663 to 0.708, with no clearly superior architecture. Bacterial-label prevalence differed by acquisition device (Samsung 9.2% versus Xiaomi 26.9%); the device-only and clinical-variable comparators achieved AUROCs of 0.650 and 0.598, respectively. At validation-selected high-sensitivity thresholds, the models flagged 65–78% of patients, with positive predictive values of only 19–22%. All models contained fewer than five million parameters, making them compact candidates for future evaluation on resource-constrained devices. Conclusions: Lightweight models showed moderate performance against physician-consensus labels. However, acquisition device was associated with the reference labels, image-model AUROCs were not clearly distinguishable from that of the device-only comparator, and device-related confounding cannot be excluded. Because performance was measured against these labels and positive predictive values were low, the findings do not establish diagnostic accuracy or clinical applicability, which require validation against microbiological reference standards in independent clinical cohorts.
8 September 2025 in Medical Rehabilitation Sciences
Mindfulness has emerged as a holistic approach that enhances psychological well-being and physiological functioning. This comprehensive review explores the relationship between mindfulness and major chronic conditions, including Diabetes Mellitus (DM), Hypertension (HTN), Insomnia, Obesity, Gastrointestinal Disorders (such as Irritable Bowel Syndrome and Inflammatory Bowel Disease), and Migraine. Evidence suggests that mindfulness-based interventions (MBIs) significantly improve disease management and quality of life across various patient populations. The review highlights recent randomized controlled trials, systematic reviews, and meta-analyses to provide an updated synthesis of the impact of mindfulness on symptom severity, metabolic parameters, inflammatory markers, and behavioral outcomes. Furthermore, the paper discusses underlying mechanisms, clinical implications, and future research directions, emphasizing mindfulness as an integrative strategy in chronic disease prevention and treatment. In particular, this review aims to explore recent innovations in mindfulness-based interventions—including digital delivery, VR applications, and condition-specific adaptations—as well as examine the contributing psychosomatic, behavioral, and physiological causes linking chronic disease with psychological distress.